Tag: BCRX

BioTech

Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Colin Pettis
Finance

Investors Should Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), American Airlines Group Inc. (NASDAQ:AAL), General Communication Inc. (NASDAQ:GNCMA), BioCryst Pharmaceuticals (NASDAQ:BCRX), OceanFirst Financial (NASDAQ:OCFC)

On Jan 22, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on Merrimack’s Board of Directors. Anthony J. Sinskey, Sc.D. will also be resigning from the Board of Directors and will continue … Continue reading Investors Should Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), American Airlines Group Inc. (NASDAQ:AAL), General Communication Inc. (NASDAQ:GNCMA), BioCryst Pharmaceuticals (NASDAQ:BCRX), OceanFirst Financial (NASDAQ:OCFC)

Chris Lewis